Press release year list 2023 2022 2021 2020 2019 2018
11/01/2022
Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies
10/18/2022
Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress
10/17/2022
Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics
10/11/2022
Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates
07/26/2022
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer
06/17/2022
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
06/07/2022
Brooklyn ImmunoTherapeutics Announces Board Changes
05/31/2022
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting
05/27/2022
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q
04/21/2022
Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
04/15/2022
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results
03/09/2022
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement
03/07/2022
Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement
01/20/2022
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors
01/13/2022
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio